Natera announced that its Prospera test was highlighted in 17 abstracts and six oral presentations at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting, which took place in Toronto, Canada. The announcement was made on April 22, 2026.
The company’s chief medical officer of organ health, Sangeeta Bhorade, M.D., said, "ISHLT 2026 marks our largest presence at the conference to date, reflecting the growing body of evidence supporting Prospera in heart and lung transplantation. What's especially compelling is not just the breadth of data, but how consistently it reinforces Prospera's role as a high‑precision, clinically actionable tool, enabling earlier detection, more refined risk stratification, and more informed decision‑making in transplant care." The expanded evidence base is intended to support broader adoption of Prospera in transplant centers and to strengthen payer coverage discussions.
Prospera’s expanded clinical validation aligns with Natera’s strategy of leveraging its cell‑free DNA platform across multiple therapeutic areas. The organ‑health segment has been a key driver of the company’s revenue growth, with total revenues rising 35.9% in 2025 to $2.306 billion. The organ‑health testing market represents a $3.8 billion opportunity, and the new ISHLT data reinforce Prospera’s positioning as a high‑precision, clinically actionable tool that can accelerate adoption and payer coverage.
The announcement underscores momentum for Natera’s organ‑health segment and signals potential acceleration of revenue growth in that area, reinforcing the company’s broader strategy to expand its cfDNA platform into additional therapeutic domains.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.